{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T10:39:41Z","timestamp":1648723181398},"reference-count":36,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hamostaseologie"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recently direct-acting oral anticoagulants (DOACs) have become a new therapeutic option besides parenteral anticoagulants to treat cancer-associated venous thromboembolism (VTE). With this survey we wanted to identify factors influencing the choice between low-molecular-weight heparin and DOACs among physicians treating cancer patients. A questionnaire was presented at several medical educational activities on cancer care and VTE management between August 2018 and January 2019. One hundred fifteen physicians returned their surveys. The two most compelling arguments pro DOAC were when the patient had no chemotherapy and when he expressed unwillingness to apply injections. The two most important arguments against DOACs were if the patient had problems with taking oral medications or when he had a history of severe bleeding. This survey shows that future studies need to consider many more factors, particularly patient preferences and physician concerns on bleeding risk, to improve their applicability in daily practice.<\/jats:p>","DOI":"10.1055\/a-1129-2573","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:11:12Z","timestamp":1588291872000},"page":"655-661","source":"Crossref","is-referenced-by-count":1,"title":["Factors Influencing the Choice between DOACs and LMWHs: A Survey of German Physicians on the Treatment of Cancer-Associated Venous Thromboembolism"],"prefix":"10.1055","volume":"40","author":[{"given":"Axel","family":"Matzdorff","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Asklepios Clinic Uckermark, Schwedt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Hemostasis Clinic and Hemophilia Center, University Medical Center Eppendorf, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"issue":"03","key":"ref1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"A A Khorana","year":"2013","journal-title":"Cancer"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH09-06-0397","article-title":"Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics","volume":"103","author":"S Paneesha","year":"2010","journal-title":"Thromb Haemost"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"A T Cohen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"F I Mulder","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.amjmed.2006.02.022","article-title":"Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer","volume":"119","author":"R D Hull","year":"2006","journal-title":"Am J Med"},{"issue":"15","key":"ref6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/archinte.162.15.1729","article-title":"Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study","volume":"162","author":"G Meyer","year":"2002","journal-title":"Arch Intern Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"A Y Lee","year":"2003","journal-title":"N Engl J Med"},{"issue":"07","key":"ref8","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"A YY Lee","year":"2015","journal-title":"JAMA"},{"issue":"04","key":"ref9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/1076029606293692","article-title":"Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period","volume":"12","author":"S R Deitcher","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"issue":"10","key":"ref11","doi-asserted-by":"crossref","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","article-title":"International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"17","author":"D Farge","year":"2016","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref14","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"S 01","key":"ref15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood-2018-99-118808","article-title":"Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial","volume":"132","author":"R D McBane","year":"2018","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.thromres.2016.07.013","article-title":"Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?","volume":"145","author":"A A Khorana","year":"2016","journal-title":"Thromb Res"},{"issue":"11","key":"ref17","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3324\/haematol.2015.127126","article-title":"Assessing patients' anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology","volume":"100","author":"S Noble","year":"2015","journal-title":"Haematologica"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.thromres.2011.07.017","article-title":"Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey","volume":"129","author":"C Cimminiello","year":"2012","journal-title":"Thromb Res"},{"issue":"43","key":"ref19","doi-asserted-by":"crossref","first-page":"26990","DOI":"10.18632\/oncotarget.25454","article-title":"Quality of life in cancer patients undergoing anticoagulant treatment with LMWH for venous thromboembolism: the QUAVITEC study on behalf of the Groupe Francophone Thrombose et Cancer (GFTC)","volume":"9","author":"D Farge","year":"2018","journal-title":"Oncotarget"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"209S","DOI":"10.1177\/1076029618804080","article-title":"Venous thromboembolism: a survey of oral anticoagulant preferences in the treatment of challenging patient populations","volume":"24","author":"G C Moyer","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/S2352-3026(14)70018-3","article-title":"Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials","volume":"1","author":"M H Prins","year":"2014","journal-title":"Lancet Haematol"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1111\/jth.13153","article-title":"Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial","volume":"13","author":"G Agnelli","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"08","key":"ref23","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"G E Raskob","year":"2016","journal-title":"Lancet Haematol"},{"issue":"01","key":"ref24","first-page":"150","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"S Schulman","year":"2015","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref25","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1378\/chest.14-0402","article-title":"Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis","volume":"147","author":"M C Vedovati","year":"2015","journal-title":"Chest"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.thromres.2014.09.039","article-title":"Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis","volume":"134","author":"M Carrier","year":"2014","journal-title":"Thromb Res"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants","volume":"136","author":"F Posch","year":"2015","journal-title":"Thromb Res"},{"issue":"07","key":"ref28","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/jth.12605","article-title":"Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism","volume":"12","author":"T van der Hulle","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"14","key":"ref29","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2013-04-460162","article-title":"Treatment of cancer-associated thrombosis","volume":"122","author":"A Y Lee","year":"2013","journal-title":"Blood"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"N J Short","year":"2014","journal-title":"Oncologist"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1159\/000380871","article-title":"Treatment of venous thromboembolism in ambulatory cancer patients in Germany: a prospective non-interventional study","volume":"38","author":"A Matzdorff","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/rth2.12002","article-title":"Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis","volume":"1","author":"A A Khorana","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"issue":"06","key":"ref33","doi-asserted-by":"crossref","first-page":"e0128741","DOI":"10.1371\/journal.pone.0128741","article-title":"Long-term anticoagulant therapy of patients with venous thromboembolism. What are the practices?","volume":"10","author":"I Mah\u00e9","year":"2015","journal-title":"PLoS One"},{"issue":"08","key":"ref34","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1007\/s00520-016-3164-8","article-title":"Adherence to treatment guidelines for cancer-associated thrombosis: a French hospital-based cohort study","volume":"24","author":"I Mah\u00e9","year":"2016","journal-title":"Support Care Cancer"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1111\/jth.13483","article-title":"Factors influencing adherence to clinical guidelines in the management of cancer-associated thrombosis","volume":"14","author":"I Mah\u00e9","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref36","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/j.1538-7836.2006.02073.x","article-title":"Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis","volume":"4","author":"A K Wittkowsky","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0038-1637943","article-title":"Managing clinical knowledge for health care improvement","volume":"9","author":"E A Balas","year":"2000","journal-title":"Yearb Med Inform"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000444734","article-title":"Practice patterns for prophylaxis and treatment of venous thromboembolism in German cancer patients","volume":"39","author":"A Matzdorff","year":"2016","journal-title":"Oncol Res Treat"}],"container-title":["H\u00e4mostaseologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1129-2573.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T23:41:29Z","timestamp":1609285289000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1129-2573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":36,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2020,12,29]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1129-2573","relation":{},"ISSN":["0720-9355","2567-5761"],"issn-type":[{"value":"0720-9355","type":"print"},{"value":"2567-5761","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]}}}